Equities analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) to post $6.58 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Atara Biotherapeutics’ earnings, with the lowest sales estimate coming in at $5.70 million and the highest estimate coming in at $8.03 million. Atara Biotherapeutics reported sales of $3.55 million during the same quarter last year, which indicates a positive year-over-year growth rate of 85.4%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Atara Biotherapeutics will report full-year sales of $70.95 million for the current year, with estimates ranging from $24.00 million to $132.10 million. For the next financial year, analysts forecast that the company will report sales of $59.28 million, with estimates ranging from $11.00 million to $134.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last released its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.36). The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $47.75 million. Atara Biotherapeutics had a negative net margin of 1,672.28% and a negative return on equity of 103.05%. During the same period in the previous year, the firm posted ($0.95) earnings per share.
In other Atara Biotherapeutics news, EVP Jakob Dupont sold 5,000 shares of the company’s stock in a transaction on Thursday, February 10th. The shares were sold at an average price of $16.00, for a total transaction of $80,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Utpal Koppikar sold 2,496 shares of the company’s stock in a transaction on Monday, February 7th. The shares were sold at an average price of $14.46, for a total transaction of $36,092.16. The disclosure for this sale can be found here. Insiders own 3.80% of the company’s stock.
Several institutional investors have recently modified their holdings of ATRA. Macquarie Group Ltd. raised its position in shares of Atara Biotherapeutics by 326.1% during the 3rd quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,534 shares during the last quarter. Point72 Hong Kong Ltd raised its position in shares of Atara Biotherapeutics by 1,155.2% during the 3rd quarter. Point72 Hong Kong Ltd now owns 7,845 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 7,220 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Atara Biotherapeutics during the 3rd quarter valued at $181,000. AlphaCrest Capital Management LLC acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at $189,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of Atara Biotherapeutics in the 3rd quarter valued at $205,000.
Shares of ATRA opened at $6.36 on Friday. The company has a market capitalization of $562.33 million, a P/E ratio of -1.75 and a beta of 1.82. Atara Biotherapeutics has a one year low of $6.31 and a one year high of $20.04. The business’s 50 day simple moving average is $9.15 and its 200-day simple moving average is $13.75.
Atara Biotherapeutics Company Profile (Get Rating)
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.